Ketamine for Combined Depression and Alcohol Use Disorder
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to investigate the effects of ketamine, in combination
with standard inpatient addiction therapy, for adults with depression and alcohol use
disorder. After screening and enrollment, participants will undergo baseline assessments of
depression, measures of alcohol use and craving, as well as neurocognitive function.
Participants will then be randomized to either ketamine (intervention) or midazolam
(control). All participants will be admitted for standard inpatient addiction therapy while
receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will
be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6
months after baseline assessment.